Celltrion

068270 · KOSPI

Public Market Listing

068270KOSPI

KOSPI primary exchange listing

Live quotes, historical charts, and market capitalization for Celltrion are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(11 total)
11Total Assets
8Approved
3Phase 3 / Filed
0Phase 1–2 / Early
19Diseases
Quick filter:
Showing 11 of 11 assets
Target & Modality
Approved
TNF-alphaMonoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid ArthritisHidradenitis SuppurativaNon-Infectious Uveitis
Ulcerative Colitis, Crohn's Disease
Approved
VEGF-AProtein / enzyme therapeutic
Age-Related Macular DegenerationDiabetic Macular Edema
Wet Age-Related Macular Degeneration
Approved
IL-6R antagonistMonoclonal antibody
Rheumatoid ArthritisCOVID-19
Approved
TNF-alphaMonoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid Arthritis
Ulcerative Colitis, Crohn's Disease
Approved
TNF-alphaMonoclonal antibody
Inflammatory Bowel Disease
Ulcerative Colitis, Crohn's Disease
Approved
CD20Monoclonal antibody
Rheumatoid ArthritisNon-Hodgkin LymphomaChronic Lymphocytic Leukemia
Approved
IL-12 p40Monoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis
Ulcerative Colitis, Crohn's Disease
Approved
VEGF-AMonoclonal antibody
Non-Small Cell Lung CancerOvarian CancerCervical CancerColorectal CancerRenal Cell CarcinomaGlioblastoma
Metastatic Colorectal Cancer, Recurrent Glioblastoma, Advanced Metastatic Colorectal Cancer
Phase 3
CD38Monoclonal antibody
Multiple Myeloma
Phase 3
PD-1Monoclonal antibody
Non-Small Cell Lung Cancer
Phase 3
CD20Monoclonal antibody
Multiple Sclerosis

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
February 2027 (2)
CT-P51Phase 3Non Squamous Non Small Cell Lung Cancer
Est. primary completion 2027-02 · NCT06939595 · CT.gov ↗
What to watch
CT-P53Phase 3Relapsing-remitting Multiple Sclerosis
Est. primary completion 2027-02 · NCT05906992 · CT.gov ↗
What to watch
March 2027 (1)
CT-P44Phase 3Refractory or Relapsed Multiple Myeloma
Est. primary completion 2027-03-08 · NCT06952478 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(6)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

24 August 2026Filing submittedCT-P51Celltrion submits a marketing application to Korea's MFDS for CT-P51, a pembrolizumab biosimilar
KR, MFDS · Celltrion · Source ↗
9 October 2025Approvalaflibercept-boav (Eydenzelt)FDA approves EYDENZELT (aflibercept-boav)
US, FDA · Source ↗
6 August 2025ApprovalCT-P47 (tocilizumab)FDA approves AVTOZMA IV for cytokine release syndrome
US, FDA · Source ↗
15 June 2025Approvalustekinumab-stba (Steqeyma)FDA approves new 45mg/0.5mL single-dose vial presentation of STEQEYMA
US, FDA · Source ↗
23 May 2025Approvaladalimumab-aaty (Yuflyma)FDA expanded interchangeability designation for Yuflyma
US, FDA · Source ↗
17 December 2024Approvalustekinumab-stba (Steqeyma)FDA approves STEQEYMA (ustekinumab-stba), a biosimilar to STELARA
US, FDA · Source ↗

Financial reports

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$2.6B—$679M—report ↗
View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-FY$1.7B—$442M—report ↗